Kornimate/medical-research-clean huggingface dataset:
validation of epworth richmond's echocardiography education focused year

Conditions: Shock, Cardiogenic; Cardiac Tamponade; Pulmonary Embolism; Hypovolemia

Summary: the use of echocardiography in intensive care is a developing field. in expert hands echocardiography has proven its utility in diagnosing cardiac pathology, differentiating shock states and in haemodynamic monitoring. however, whether the results obtained by experts can be generalized to trainees or specialists with limited training remains unclear. further, concerns around training time and cost for intensive care staff have been a factor in limiting the uptake of echocardiography in intensive care. the investigators aim to assess the diagnostic accuracy of australian icu doctors in training after completion of the current minimum training. after completing a structured teaching program and 30 mentored training scans trainees will be assessed on their accuracy with echocardiography. in the research phase trainees will complete a further 40 scans with each one matched with an expect scan. the results from the expert and trainee scans will be compared to determine the trainee's accuracy.


Eligibility criteria:
registrar inclusion: * at least 12 month appointment in epworth richmond icu * completion of theoretical component of epworth richmond icu echocardiography program * completion of 30 echocardiography scans registrar exclusion: • previous experience in echocardiography prior to commencing at epworth richmond. patient inclusion * patient in icu or ccu * 18 years or older * not likely to be discharged before completion of the scan patient exclusion * likely to be discharged within next two hours * atrial fibrillation * presence of subcostal or intercostal drains or pneumothorax * unable to be consented * treating intensivist deems inclusion in study not suitable.
adaptation of conventional versus virtually fabricated ear prosthesis in patients with auricular defects

Conditions: Ear Deformity External

Summary: : patients were recruited for auricular prosthetic reconstruction. preoperative data was collected including personal and medical history, plain photographs and ct scans. pre-operative prosthetic and implant planning were carried out. three endosseous implants were placed in a two-stage surgical technique. patients were assigned into two groups with allocation ratio 1:1. in control group, implant level impression was recorded, and a stone model of the defect was cast. waxing up of the ear was done on the stone cast followed by flasking, wax elimination, packing of heat cured acrylic resin and curing. in intervention group, ct scanning was done to the full head and optical scanning was done to the defect site with scan bodies screwed to the implants. using exocad software a model of the defect site with implant analogues and ear model with abutment extensions were planned and printed using sla printing technology. a placement jig was done for ear models of both groups and adaptation was measured on the patient using silicon replica technique. the silicone replica was sectioned and the gap, represented in light consistency polyvinyl siloxane impression material was measured using digital microscope.


Eligibility criteria:
inclusion criteria: * patients with missing or severely deformed ears. * patients with failed autogenous reconstruction. * compliant and cooperative patients. * patients committed to maintain the prosthesis. * patients willing to attend the follow up appointments. exclusion criteria: * patients undergoing radiotherapy or chemotherapy treatment. * patients taking corticosteroids or bisphosphonates. * patients with contraindications for ct scanning. * patients with any debilitating medical condition. * patients with any type of psychosomatic disorder. * patients allergic to any of the materials used.
norepinephrine and phenylephrine for maternal cardiac output during spinal anesthesia for elective cesarean delivery

Conditions: Hypotension

Summary: the purpose of this study is to compare norepinephrine and phenylephrine on the effects of maintaining the cardiac output in cesarean section under spinal anesthesia.

co was measured using the nicom® monitor. bioreactance, a development from impedance technology, is also emerging as an accessible mode of continuous co monitoring in the operating room and can provide valuable insight into the hemodynamic effects of our interventions. this method of monitoring provides continuous co, stroke volume (sv) and heart rate (hr) monitoring, and intermittent bp and svr assessments at 1-minute intervals. either phenylephrine (100 mcg/ml) or norepinephrine (0.5 mcg/ml) in 50-ml syringe that were labeled "study drug". she was not involved in patient's care or study assessment. the hypotension was defined as systolic blood pressure \<80% of baseline or \< 90 mmhg, and managed with study drug (1 ml) intravenously. the bradycardia was defined as hr \< 60 beats/min and was recorded and managed with atropine (0.5 mg) intravenously as hr \< 45 beats/min. the presence of nausea and vomiting was measured on a 3 point scale (1 = no nausea and vomiting, 2 = nausea only, and 3 = both nausea and vomiting) and managed with ondansetron (4mg) intravenously.

Eligibility criteria:
inclusion criteria: * asa class i and ii, term pregnancy (gestational age\>37weeks), planned spinal anesthesia for elective cesarean section exclusion criteria: * preexisting or gestational hypertension, cerebrovascular or cardiovascular disease, any contraindication to the spinal anesthesia, fetal anormaly, weight\ 100kg, and height\ 180cm.
substance misuse to psychosis for ketamine (stop-k)

Conditions: Ketamine Abuse; Psychotic Disorders; Substance Use Disorders; Schizophrenia; Genetic Predisposition

Summary: evidence suggests that repeated or chronic ketamine use, as compared to acute ketamine users, posed a higher clinical risk of developing psychotic disorders, potentially related to the underlying chronic n-methyl-d-aspartate receptor (nmdar) dysfunction, and a higher risk of suffering from schizophrenia particularly in those genetically susceptible, or genetically predisposed ketamine abusers. with ketamine infusion rises as a emerging hope as an acute treatment for depression and suicidality under the shadow of unknown longer term psychotomimetic effects peculiarly amongst repeated or chronic use, the current case-control study aims to investigate: a) if repeated or chronic ketamine use is associated with an increased risk of psychosis by comparing those ketamine abusers with and without psychosis, and to those non-ketamine-using drug abusers with psychosis; and b) if genetic predisposition from single nucleotide polymorphisms are associated with risk of psychosis in ketamine abusers.


Eligibility criteria:
inclusion criteria: * age: 12 - 65 years old * able to read and communicate in english and/or chinese * able to give informed consent * self-reported to have psychoactive substance use continuously for ≥3 month * at least one positive urine toxicology result showing the reported psychoactive substance being used exclusion criteria: * age \<12 years old * unable to read english or chinese * unable to give informed consent * had been diagnosed to have intellectual disabilities (dsm-5) or mental retardation (icd-10, f70-73) * had been diagnosed to have primary psychosis prior to the use of any psychoactive substances, including alcohol * had been diagnosed to have "bipolar and related disorder" prior to the use of any psychoactive substances, including alcohol * had been diagnosed to have "major depressive disorder with psychotic features" prior to the use of any psychoactive substances, including alcohol * had been diagnosed to have "psychotic disorder due to another medical condition" (dms-5) * self-reported to have abstained from any psychoactive substance use continuously for ≥12 months and with negative urine toxicology result at the time of recruitment/ intake at the psychiatric services as recorded on case notes
study of proteins in tumor samples from patients with non-small cell lung cancer

Conditions: Lung Cancer

Summary: this research studies protein in tumor samples from patients with non-small cell lung cancer. finding specific proteins in tumor tissue samples from patients with cancer may help doctors tell what type of lung cancer a patient has and plan better treatment.

primary objectives: i. to validate a novel 4-protein signature's ability to subtype non-small cell lung cancer (nsclc) in a treatment-naive, multi-institutional cohort, cancer and leukemia group b (calgb) 9761. secondary objectives: i. to estimate the nsclc misclassification rate in a multi-institutional clinical-trial setting for stage 1 nsclc (adenocarcinoma versus squamous cell). outline: previously collected tissue samples are analyzed via hematoxylin and eosin (h\&e) staining and immunohistochemistry (ihc).

Eligibility criteria:
inclusion criteria: * patients must have been registered on calgb-9761 * stage i disease * treatment-naive patients * a representative paraffin block of the primary tumor must be available from patients on calgb-9761 and submitted to the calgb pathology coordinating office * a separate consent form is not required for this study, as permission for research to be performed on the tissue blocks is included in the consent form for calgb 9761 * institutional review board (irb) review and approval at the institution where the laboratory work will be performed is required

Keywords: stage ia non-small cell lung cancer stage ib non-small cell lung cancer adenocarcinoma of the lung squamous cell lung cancer
post-surgical delirium in patients undergoing radical cystectomy.

Conditions: Delirium; Radical Cystectomy

Summary: post-surgical delirium in patients undergoing radical cystectomy. introduction delirium occurs after major abdominal surgery may reach about 15% of the patients.(1) aim the aim of this study is to determine the incidence of delirium after radical cystectomy surgery and the associated risk factors in alexandria university hospital. patients and methods after approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in alexandria university hospitals from january 5th 2019 till january 4th 2020. the 6-item cognitive impairment test (6cit) and spmsq questionnaire will be used. spmsq will be done preoperative and daily for 3 days postoperative, at day 7. phone call for spmsq will be done 3, 6, 9 and 12 months after surgery.

post-surgical delirium in patients undergoing radical cystectomy. introduction delirium occurs after major abdominal surgery may reach about 15% of the patients.(1) aim the aim of this study is to determine the incidence of delirium after radical cystectomy surgery and the associated risk factors in alexandria university hospital. patients and methods after approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in alexandria university hospitals from january 5th 2019 till january 4th 2020. the 6-item cognitive impairment test (6cit) and spmsq questionnaire will be used. spmsq will be done preoperative and daily for 3 days postoperative, at day 7. phone call for spmsq will be done 3, 6, 9 and 12 months after surgery. results results will be collected in tables and graphs. appropriate statistical analysis will be done. discussion results of the study will be discussed compared to other studies.

Eligibility criteria:
inclusion criteria:adult patients undergoing radical cystectomy. - exclusion criteria: patient refusal. -
suan tsao jen tang for treating menopause with sleep problem: a clinical observation

Conditions: Menopausal and Female Climacteric States

Summary: a prospective follow-up study was carried out in the yang ming branch of the taipei city hospital.climacteric women with sleep difficulty received szrt at a rate of 4.0 g, thrice daily for four weeks.

a prospective follow-up study was carried out in the yang ming branch of the taipei city hospital between april 2008 and april 2010. sixty-seven climacteric women with sleep difficulty received szrt at a rate of 4.0 g, thrice daily for four weeks. baseline scores were measured on the pittsburg sleep quality index (psqi), followed by further measures at the end of weeks one and four. the world health organization quality of life (whoqol) assessment and the menopause rating scale (mrs) were undertaken as secondary outcomes. regression models were constructed to explore the score differences between the baseline and at weeks one and four by various determinants including age, body mass index (bmi), and severity of baseline menopausal symptoms. among 99 surveyed patients, 67 and 61 were screened for intention to treat (itt) and per-protocol population set analysis, respectively. statistically significant reductions in the psqi index scores evidenced on the fourth week.

Eligibility criteria:
inclusion criteria: 1. climacteric women, ranging from 40-65 years of age 2. pittsburg sleep quality index (psqi) of greater than six 3. falling asleep more than 45 minutes or slept less than six hours exclusion criteria: 1. within three months of the study there had been a major incident 2. working the nightshift 3. lack of time or timing conflicts 4. pychosis, severe depression, obstructive sleep apnea-hypopnea, cardiac arrhythmia, acute myocardial infarction, high blood pressure, diabetes, or cancer 5. currently taking pharmaceuticals that affect melatonin, acetylcholine, glutamate, serotonin, norepinephrine, gaba, histamine, adenosine, or prostaglandins 6. inability to read and fill out the forms for the study 7. any evidence of renal or liver dysfunction as defined by a level of at least 1.5 times of the upper reference limit

Keywords: suan zao ren tang, climacteric, psqi, whoqol-bref
sbrt and ldrt combined with pd-1 antibody and chemotherapy in r/m nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: this is a prospective, single-arm, phase ii clinical trial. the purpose of this study is to evaluate the efficacy and adverse effect of sbrt and ldrt combined with programmed death 1 (pd-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.


Eligibility criteria:
inclusion criteria: * diagnosed as recurrence/metastatic npc * histopathological diagnosis of npc(who ii/iii) * ecog 0-1 point * no treatment to r/mnpc, such as radiotherapy, chemotherapy, immunotherapy or biotherapy; * no contraindications to immunotherapy and chemoradiotherapy; * at least one lesion could receive sbrt safely; * subject must have a measurable target lesion based on recist v1.1; * adequate marrow function: wbc count ≥ 3×10e9/l, ne count ≥ 1.5×10e9/ l, hgb ≥ 90g/l, plt count ≥ 100×10e9/l; * adequate liver function: alt/ast ≤ 2.5×uln, tbil ≤ 2.0×uln; * adequate renal function: bun/cre ≤ 1.5×uln or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula); * take effective contraceptions during and three months after treatment; * patients must be informed of the investigational nature of this study and give written informed consent. exclusion criteria: * allergic to monoclonal antibodies, any pd-1 antibody components, gemcitabine and cisplatin; * unexplained fever \> 38.5 #, except for tumor fever; * have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy); * have a known history of human immunodeficiency virus (hiv), active hepatitis b (hbv-dna ≥10e3copiers/ml) or hepatitis c virus (hcv) antibody positive; * have new york heart association (nyha) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment; have known allergy to large molecule protein products or any compound of study therapy; * pregnant or breastfeeding; * prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma; * have received a live vaccine within 30 days of planned start of study therapy has psychiatric drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial; * any other condition, including mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.

Keywords: sbrt low-dose radiotherapy pd-1 antibody chemotherapy
mri-guided cryoablation for focal native prostate cancer

Conditions: Primary Malignant Neoplasm of Prostate (Diagnosis)

Summary: the purpose of this research is to collect data about the mri cryoablation procedure your doctor(s) would normally perform in order to treat the participants focal prostate cancer and to evaluate the participants condition after the participants treatment is performed. participants have been asked to take part in this research because the participants have been diagnosed with prostate cancer and scheduled to have an ablation procedure.

the purpose of this study is to evaluate mr-guided cryoablation of biopsy proven prostate tumors using the galil mri-compatible cryoablation system. the system has been approved by the united states food and drug administration (fda) for soft tissue ablation and has been utilized successfully at mayo. all procedures will be performed according to approved indications. the investigators wish to monitor the technique and collect data at the participants follow-up visits. the study only collects data about the mri-guided cryoablation procedure the participants doctor(s) would normally perform in order to treat the participants focal prostate cancer and to evaluate the participants condition after there treatment is performed. the participants doctor will advise the participants when the participants should return for follow-up visits. these visits will be according to the participants doctor's standard of care; usually return visits are at 3-6months, 12 months, 24 months, 36 months, 48 months and 60 months after the procedure, although the participants doctor may ask that the participants return for more frequent visits.

Eligibility criteria:
inclusion criteria: * patients with "biopsy proven" gleason7 prostate cancer referred to urology and/or interventional radiology for treatment * surgery and/or radiation is not a desirable alternative therapy at the time of enrollment * tumor size is \< 2 cm at its largest diameter * tumor does not encompass the rectal wall or external urethral sphincter * patient is able to undergo mri exclusion criteria: •
a study to evaluate the efficacy and safety of inavolisib in combination with phesgo versus placebo in combination with phesgo in participants with pik3ca-mutated her2-positive locally advanced or metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: this study will evaluate the efficacy and safety of inavolisib in combination with phesgo (pertuzumab, trastuzumab, and rhuph20 injection for subcutaneous use) compared with placebo in combination with phesgo, as maintenance therapy, after induction therapy in participants with previously untreated her2-positive advanced breast cancer (abc).


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status 0 or 1 * histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally advanced disease not amenable to curative resection * confirmation of her2 biomarker eligibility based on valid results from central testing of tumor tissue documenting her2-positivity * confirmation of pik3ca-mutation biomarker eligibility based on valid results from central testing of tumor tissue documenting pik3ca-mutated tumor status * disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of \>= 6 months * lvef (left ventricular ejection fraction) of at least 50% measured by echocardiogram (echo) or multiple-gated acquisition scan (muga) * adequate hematologic and organ function prior to initiation of study treatment exclusion criteria: * prior treatment in the locally advanced or metastatic setting with any pi3k, akt, or mtor inhibitor or any agent whose mechanism of action is to inhibit the pi3k-akt-mtor pathway * any prior systemic non-hormonal anti-cancer therapy for locally advanced or metastatic her2-positive breast cancer prior to initiation of induction therapy * history or active inflammatory bowel disease * disease progression within 6 months of receiving any her2-targeted therapy * type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of type 1 diabetes * participants with active hbv infection * clinically significant and active liver disease, including severe liver impairment, viral or other hepatitis, current alcohol abuse, or cirrhosis * symptomatic active lung disease, including pneumonitis or interstitial lung disease * any history of leptomeningeal disease or carcinomatous meningitis * serious infection requiring iv antibiotics within 7 days prior to day 1 of cycle 1 * any concurrent ocular or intraocular condition that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition * active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye